Wren Capital is an early stage angel investor focusing on science, software, and engineering start-ups.
Portfolio
9
companies
Adapttech
Adapttech develops wearable biomedical technologies to improve the quality of life for people with physical limitations.
.png)
Antiverse
Antiverse develops AI-designed therapeutic antibodies for challenging disease targets using computational platforms and in-house laboratories.
HotHouse Therapeutics
HotHouse Therapeutics develops sustainable pharmaceutical compounds using an AI-optimised plant-based chemistry platform.
Keit
Keit manufactures robust spectrometer technology for industrial process monitoring.
MitoRx Therapeutics
Developing targeted therapeutics to arrest the progression of degenerative diseases.
Monument Therapeutics
Monument Therapeutics develops stratified treatments for central nervous system conditions using digital brain biomarkers.
PharmEnable
PharmEnable develops next-generation small molecule drugs for challenging disease targets using an artificial intelligence platform.
Singular Photonics
Developer of intelligent image sensors that count individual photons.
Spotta
Spotta creates connected monitoring devices for insect pest management across various industries.
Rajat Malhotra
Managing Partner
Rajat brings investment experience from roles at Wren Capital, ACF Investors, and Cambridge Angels. He also serves as a non-executive director at Momentum Bioscience.
LinkedInThe oversubscribed round will fund a next-generation sensor tape-out and team expansion following a surge in sales.
"We’ve already doubled our 2025 sales, we’re approaching break-even, and our customers are telling us exactly what they want from future product"
The Norwich-based drug discovery startup emerged from stealth with backing from SynBioVen, Start Codon, UKI2S, Twin Path Ventures, Wren Capital, angels, and Innovate UK.
"We grow greener medicines using a platform that makes the impossible accessible. The drug discovery field desperately needs new chemical space and the vaccine field needs new adjuvants, with supply chains that work for everyone. By combining AI with plant engineering, we can reach molecules others cannot, and scale them in a way that supports global health, not just high-income markets."
The funding round was led by The Yield Lab, STIHL Ventures, and ACF Investors to drive global product growth.
"The Spotta platform built by Robert, Neil and the team delivers a real solution which can completely turn the insect pest control industry on its head. With their smart 24/7 monitoring enabling customers to precision target treatment for the first time. It’s a solution that protects people and crops but also hugely reduces the cost and environmental impact of treatment."
MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.
"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
Science Angel Syndicate backed the funding round alongside a broad group of institutional and angel investors.
"I've long been fascinated by how reversing mitochondrial dysfunction could arrest the progression of degenerative diseases, which place great burdens on patients and healthcare systems. This seed financing will enable us to advance MitoRx's first-in-class therapeutic pipeline. We are the first biotech to address dysfunction of sulfide-signalling, a fundamental part of life's energy systems. I'm also delighted to welcome Glyn to the team whose wealth of experience will be a great asset as we accelerate our novel pipeline of small molecule mitochondrial protective therapeutics towards the clinic."
